In vitro activities of ER-119884 and E5700, two potent squalene synthase inhibitors, against Leishmania amazonensis: Antiproliferative, biochemical, and ultrastructural effects

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 11, 2008, Pages 4098-4114

  Rodrigues, Juliany Cola Fernandes ^a   Concepcion, Juan Luis ^b   Rodrigues, Carlos ^c   Caldera, Aura ^c   Urbina, Julio A ^c   De Souza, Wanderley ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FACULTAD DE CIENCIAS   (Venezuela)

^c INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[2 BENZYL 6 (3 HYDROXY 4 METHOXYPYRROLIDIN 1 YL)PYRIDIN 3 YL]ETHYNYL]QUINUCLIDIN 3 OL; 3 [[2 BENZYL 6 (3 METHOXYPROPYLOXY)PYRIDIN 3 YL]ETHYNYL]QUINUCLIDIN 3 OL; E 5700; ER 119884; FLUORESCENT DYE; SQUALENE SYNTHASE; SQUALENE SYNTHASE INHIBITOR; STEROL; TRYPAN BLUE; TUBULIN; UNCLASSIFIED DRUG;

ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; CYTOKINESIS; CYTOSKELETON; DRUG POTENCY; DRUG SELECTIVITY; ELECTRON MICROSCOPY; ENDOPLASMIC RETICULUM; FLAGELLUM; GOLGI COMPLEX; HOST CELL; IC 50; IN VITRO STUDY; LEISHMANIA; LEISHMANIA MEXICANA; MACROPHAGE; MITOCHONDRION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; ULTRASTRUCTURE;

ANIMALS; ANTIPROTOZOAL AGENTS; CYTOSKELETON; ENZYME INHIBITORS; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; HUMANS; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; PYRIDINES; QUINUCLIDINES; STEROLS; TUBULIN;

EID: 55849131057     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01616-07     Document Type: Article

References (55)

1. Barral, A., D. Pedral-Sampaio, G. Grimaldi, Jr., H. Momen, D. McMahon-Pratt, A. R. de Jesus, R. Almeida, R. Badaró, M. Barral, and E. M. Carvalho. 1991. Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am. J. Trop. Med. Hyg. 44:536-546.
2. Barrett-Bee, K., and N. Ryder. 1992. Biochemical aspects of ergosterol biosynthesis inhibition, p. 437-475. In J. Sutcliffe, and N. H. Georgopapadakou (ed.), Emerging targets in antibacterial and antifungal chemotherapy. Chapman & Hall, New York, NY.
3. Berman, J. 2005. Recent developments in leishmaniasis: epidemiology, diagnosis, and treatment. Curr. Infect. Dis. Rep. 7:33-38.
4. Braga, M. V., J. A. Urbina, and W. de Souza. 2004. Effects of squalene synthase inhibitors on the growth and ultrastructure of Trypanosoma cruzi. Int. J. Antimicrob. Agents 24:72-78.
5. Brown, G. R., D. S. Clarke, A. J. Foubister, S. Freeman, P. J. Harrison, M. C. Johnson, K. B. Mallion, J. McCormick, F. McTaggart, A. C. Reid, G. J. Smith, and M. J. Taylor. 1996. Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors. J. Med. Chem. 39:2971-2979.
6. Cammerer, S., C. J. Jimenez, S. Jones, L. Gros, S. O. Lorente, C. Rodriguez, J. C. F. Rodrigues, A. Caldera, L. M. Ruiz-Pérez, W. de Souza, M. Kaiser, R. Brun, J. A. Urbina, D. Gonzalez-Pacanowska, and I. H. Gilbert. 2007. Quinuclidine derivatives as potential anti-parasitics. Antimicrob. Agents Chemother. 51:4049-4061.
7. Charlton-Menys, V., and P. N. Durrington. 2007. Squalene synthase inhibitors: clinical pharmacology and cholesterol-lowering potential. Drugs 67:11-16.
8. Concepcion, J. L., D. Gonzalez-Pacanowska, and J. A. Urbina. 1998. 3-Hydroxy-3-methyl-glutaryl-CoA reductase in Trypanosoma (Schyzotrypanum) cruzi: subcellular localization and kinetic properties. Arch. Biochem. Biophys. 352:114-120.
9. Contreras, L. M., J. Vivas, and J. A. Urbina. 1997. Altered lipid composition and enzyme activities of plasma membranes from Trypanosoma (Schizotrypanum) cruzi epimastigotes grown in the presence of sterol biosynthesis inhibitors. Biochem. Pharmacol. 53:697-704.
10. Croft, S. L., M. P. Barrett, and J. A. Urbina. 2005. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol. 21:508-512.
11. Croft, S. L., S. Sundar, and A. H. Fairlamb. 2006. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 19:111-126.
12. ν-src possibly involved in yeast cell cycle control: positive in vivo regulation by sterol. Proc. Natl. Acad. Sci. USA 84:4012-4016.
13. Dantas, A. P., H. S. Barbosa, and S. L. de Castro. 2003. Biological and ultrastructural effects of the anti-microtubule agent taxol against Trypanosoma cruzi. J. Submicrosc. Cytol. Pathol. 35:287-294.
14. Denny, P. W., D. Goulding, M. A. J. Ferguson, and D. F. Smith. 2004. Sphingolipid-free Leishmania are defective in membrane trafficking, differentiation and infectivity. Mol. Microbiol. 52:313-327.
15. Frankel, D. J., J. R. Pfeiffer, Z. Surviladze, A. E. Johnson, J. M. Oliver, B. S. Wilson, and A. R. Burns. 2006. Revealing the topography of cellular membrane domains by combined atomic force microscopy/fluorescence imaging. Biophys. J. 90:2404-2413.
16. Gaber, R. F., D. M. Copple, B. K. Kennedy, M. Vidal, and M. Bard. 1989. The yeast gene ERG6 is required for normal membrane function but is not essential for biosynthesis of the cell-cycle sparking sterol. Mol. Cell. Biol. 9:3447-3456.
17. Ganguly, N. K. 2002. Oral miltefosine may revolutionize treatment of visceral leishmaniasis. The potential impact of miltefosine on visceral leishmaniasis in India. TDR News 98:2.
18. Gonzalez-Pacanowska, D., B. Arison, C. M. Havel, and J. A. Watson. 1988. Isopentenoid synthesis in isolated embryonic Drosophila cells. Farnesol catabolism and -oxidation. J. Biol. Chem. 26:1301-1306.
19. Granthon, A. C., M. V. Braga, J. C. F. Rodrigues, S. Cammerer, S. O. Lorente, I. H. Gilbert, J. A. Urbina, and W. de Souza. 2007. Alterations on the growth and ultrastructure of Leishmania chagasi induced by squalene synthase inhibitors. Vet. Parasitol. 146:25-34.
20. Gull, K. 1999. The cytoskeleton of trypanosomatid parasites. Annu. Rev. Microbiol. 53:629-655.
21. Hirst, S. I., and L. A. Stapley. 2000. Parasitology: the drawn of a new millennium. Parasitol. Today 16:1-3.
22. Hiyoshi, H., M. Yanachimachi, M. Ito, N. Yasuda, T. Okada, H. Ikuta, D. Shinmyo, K. Tanaka, N. Kurusu, I. Yoshida, S. Abe, T. Saeki, and H. Tanaka. 2003. Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes. J. Lipid Res. 44:128-135.
23. Lazardi, K., J. A Urbina, and W. de Souza. 1990. Ultrastructural alterations induced by two ergosterol biosynthesis inhibitors, ketoconazole and terbinafine, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. 34:2097-2105.
24. Lazardi, K., J. A. Urbina, and W. de Souza. 1991. Ultrastructural alterations induced by ICI 195,739, a bis-triazole derivative with strong antiproliferative action against Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. 35:736-740.
25. Liendo, A., G. Visbal, M. M. Piras, R. Piras, and J. A. Urbina. 1999. Sterol composition and biosynthesis in Trypanosoma cruzi amastigotes. Mol. Biochem. Parasitol. 104:81-91.
26. Lorente, S. O., R. Gomez, C. J. Jimenez, S. Cammerer, V. Yardley, K. de Luca-Fradley, S. L. Croft, L. M. Ruiz-Perez, J. A. Urbina, D. Gonzalez-Pacanowska, and I. H. Gilbert. 2005. Biphenylquinuclidines as inhibitors of squalene synthase and growth of parasitic protozoa. Bioorg. Med. Chem. 13:3519-3529.
27. Lorente, S. O., J. C. F. Rodrigues, C. J. Jimenez, M. Joyce-Menekse, C. Rodriguez, S. L. Croft, V. Yardley, K. de Luca-Fradley, L. M. Ruiz-Perez, J. A. Urbina, W. de Souza, D. Gonzalez-Pacanowska, and I. H. Gilbert. 2004. Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis. Antimicrob. Agents Chemother. 48:2937-2950.
28. Luis, L., A. Ramirez, C. M. Aguilar, S. Eresh, D. C. Barker, and A. Mendoza-Leon. 1998. The genomic fingerprint of the coding region of the beta-tubulin in Leishmania identification. Acta Trop. 69:310-316.
29. Magaraci, F., C. C. Jimenez, C. Rodriguez, J. C. F. Rodrigues, M. V. Braga, V. Yardley, K. de Luca-Fradley, L. M. Ruiz-Perez, J. A. Urbina, W. de Souza, D. Gonzalez-Pacanowska, and I. H. Gilbert. 2003. Azasterols as inhibitors of sterol 24-methyltransferase in Leishmania species and Trypanosoma cruzi. J. Med. Chem. 46:4714-4727.
30. Marsden, P. D., and T. C. Jones. 1985. Clinical manifestations, diagnosis and treatment of leishmaniasis, p. 183-198. In K. P. Chang and R. S. Bray (ed.), Human parasitic diseases, leishmaniasis, vol. 1. Elsevier Science Publishers, New York, NY.
31. Martin, O. C., M. E. Comly, E. J. Blanchette-Mackie, P. G. Pentchev, and R. E. Pagano. 1993. Cholesterol deprivation affects fluorescence properties of a ceramide analog at the Golgi apparatus of living cells. Proc. Natl. Acad. Sci. USA 90:1661-1665.
32. Martins-Duarte, E. S., J. A. Urbina, W. de Souza, and R. C. Vommaro. 2006. Antiproliferative activities of two novel quinuclidine inhibitors against Toxoplasma gondii tachyzoites in vivo. J. Antimicrob. Chemother. 58:59-65.
33. McTaggart, F., G. R. Brown, R. G. Davidson, S. Freeman, G. A. Holdgate, K. B. Mallion, D. J. Mirrlees, G. J. Smith, and W. H. Ward. 1996. Inhibition of squalene synthase of rat liver by novel 3′-substituted quinuclidines. Biochem. Pharmacol. 51:1477-1487.
34. Murphy, D. J. 2001. The biogenesis and functions of lipid bodies in animals, plants and microorganisms. Prog. Lipid Res. 40:325-438.
35. Palmié-Peixoto, I., M. R. Rocha, J. A. Urbina, W. de Souza, M. Einicker-Lamas, and M. C. M. Motta. 2006. Effects of sterol biosynthesis inhibitors on endosymbiont-bearing trypanosomatids. FEMS Microbiol. Lett. 255:33-42.
36. Roberts, C. W., R. McLeod, D. W. Rice, M. Ginger, M. L. Chance, and L. J. Goad. 2003. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol. Biochem. Parasitol. 126:129-142.
37. Rodrigues, J. C. F., C. F. Bernardes, G. Visbal, J. A. Urbina, A. E. Vercesi, and W. de Souza. 2007. Sterol methenyl transferase inhibitors alter the ultrastructure and function of the Leishmania amazonensis mitochondrion leading to potent growth inhibition. Protist 158:447-456.
38. 24(25)-sterol methyltransferase inhibitors, on promastigote and amastigote forms of Leishmania amazonensis. Antimicrob. Agents Chemother. 46:487-499.
39. Rodrigues, J. C. F., J. A. Urbina, and W. de Souza. 2005. Antiproliferative and ultrastructural effects of BPQ-OH, a specific inhibitor of squalene synthase, on Leishmania amazonensis. Exp. Parasitol. 111:230-238.
40. Salto, M. L., L. E. Bertello, M. Vieira, R. Docampo, S. N. Moreno, and R. M. Lederkremer. 2003. Formation and remodeling of inositophosphoceramide during differentiation of Trypanosoma cruzi form trypomastigote to amastigote. Eukaryot. Cell 2:756-768.
41. Sealey-Cardona, M., S. Cammerer, S. Jones, L. M. Ruiz-Pérez, R. Brun, I. H. Gilbert, J. A. Urbina, and D. González-Pacanowska. 2007. Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives. Antimicrob. Agents Chemother. 51:2123-2129.
42. Sinderman, H., S. L. Croft, K. R. Engel, W. Bommer, H. J. Eibl, C. Unger, and J. Engel. 2004. Miltefosine (Impavido): the first oral treatment against leishmaniasis. Med. Microbiol. Immunol. 193:173-180.
43. Tait, R. M. 1992. Development of a radiometric spot-wash assay for squalene synthase. Anal. Biochem. 203:310-316.
44. Urbina, J. A., C. E. Osorno, and A. Rojas. 1990. Inhibition of phosphoenol pyruvate carboxykinase from Trypanosoma (Schizotrypanum) cruzi epimastigotes by 3-mercaptopicolinic acid: in vitro and in vivo studies. Arch. Biochem. Biophys. 282:91-99.
45. Urbina, J. A., G. Payares, C. Sanoja, J. Molina, R. Lira, Z. Brener, and A. J. Romanha. 2003. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int. J. Antimicrob. Agents 21:39-48.
46. Urbina, J. A., G. Payares, C. Sanoja, R. Lira, and A. J. Romanha. 2003. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int. J. Antimicrob. Agents 21:27-38.
47. Urbina, J. A. 1997. Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology 114:S91-S99.
48. Urbina, J. A., J. L. Concepcion, A. Caldera, G. Payares, C. Sanoja, T. Otomo, and H. Hiyoshi. 2004. In vitro and in vivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi. Antimicrob. Agents Chemother. 48:2379-2387.
49. Urbina, J. A., J. L. Concepcion, S. Rangel, G. Visbal, and R. Lira. 2002. Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania amazonensis. Mol. Biochem. Parasitol. 125:35-45.
50. 31P NMR spectroscopy. Biochim. Biophys. Acta 1238:163-176.
51. 24(25)-sterol methyltransferase inhibitors on Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Chemotherapy 42:294-307.
52. 24(25)-sterol methyltransferase inhibitors and their combinations with ketoconazole. Int. J. Antimicrob. Agents 7:235-240.
53. WHO. 1990. Control of the leishmaniasis. Report of a WHO expert committee. W. H. O. Tech. Rep. Ser. 793:1-158.
54. Zhang, K., F.-F. Hsu, D. A. Scott, R. Docampo, J. Turk, and S. M. Beverley. 2005. Leishmania salvage and remodeling of host sphingolipids in amastigote survival and acidocalcisome biogenesis. Mol. Microbiol. 55:1566-1578.
55. Zhang, K., M. Showalter, J. Revollo, F.-F. Hsu, J. Turk, and S. M. Beverley. 2003. Sphingolipids are essential for differentiation but not growth in Leishmania. EMBO J. 22:6016-6026.